☆ 4.8 Letter

Insulin Receptor A and IGF-1R in AML - Letter

CANCER RESEARCH (2010)

Journal

CANCER RESEARCH

Volume 70, Issue 17, Pages 7010-7010

Publisher

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/0008-5472.CAN-10-0136

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

IGF/IGF-1R signal pathway in pain: a promising therapeutic target

Lulin Ma, Wenjing Zhao, Shiqian Huang, Feng Xu, Yafeng Wang, Daling Deng, Tianhao Zhang, Shaofang Shu, Xiangdong Chen

Summary: Pain, an important problem in medicine and public health, has significant research significance. Opioids are currently the main drugs used to relieve pain, but their use is limited due to obvious side effects. Therefore, there is an urgent need to develop new drugs for pain relief. Multiple studies have shown that the IGF/IGF-1R pathway plays a crucial role in the occurrence and development of pain. This review summarizes and discusses the therapeutic potential of the IGF/IGF-1R signal pathway for pain. It also highlights the regulation of pain by IGF/IGF-1R through actions on neuronal excitability, neuroinflammation, glial cells, apoptosis, and more. However, further research is still needed to fully understand the mechanisms of pain occurrence and development. In conclusion, while more in-depth studies are required, these findings suggest that the IGF/IGF-1R signal pathway holds promise as a therapeutic target for pain.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Disrupting Insulin and IGF Receptor Function in Cancer

Jingran Cao, Douglas Yee

Summary: The IGF system plays a crucial role in regulating malignancies, but blocking this system has not shown significant benefits in clinical trials. Targeting Type I IGF receptor alone may not be sufficient to disrupt this pathway, as the insulin receptor may also play a relevant role as a cancer target.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer

Zhenling Zhang, Yuxin Zhang, Si Lao, Jian Qiu, Ziang Pan, Xiaoying Feng

Summary: This study identified IGF-1R and Livin as potential biomarkers for colorectal cancer (CRC) tumorigenesis. High expression of IGF-1R and Livin was associated with clinicopathological features of CRC and IGF-1R promoter methylation level. Additionally, elevated levels of IGF-1R and Livin were independent risk factors for stage and metastasis, and high expression of these proteins correlated with prolonged overall disease-free survival in CRC patients.

BMC CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Roles of the IGF Axis in the Regulation of the Metabolism: Interaction and Difference between Insulin Receptor Signaling and IGF-I Receptor Signaling

Tomoko Okuyama, Mayu Kyohara, Yasuo Terauchi, Jun Shirakawa

Summary: IGFs mainly mediate long-term actions in cell fates, while insulin predominantly exerts its role on metabolic activities. The interactions between insulin receptor signaling and IGF-I receptor signaling in metabolism and cell fates are complicated, and the function of IGF-I in respective tissues remains insufficiently understood. Clarifying the precise roles of IGF-I signaling on metabolism separate from those of insulin signaling is necessary.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Immunology

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy

Xuejiao Cui, Futao Wang, Cong Liu

Summary: "Recent Advances in Research on Graves' Orbitopathy (GO)" is a review article that focuses on the target cells and target antigens involved in the pathogenesis of GO. It highlights the role of orbital fibroblasts (OFs), orbital adipocytes (OAs), thyrotropin receptor (TSHR), and insulin-like growth factor-1 receptor (IGF-1R) in GO. The review also mentions the increasing trials of TSHR-inhibiting therapies and the potential therapeutic use of Teprotumumab.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Aging Regulated Through a Stability Model of Insulin/Insulin Growth Factor Receptor Function

Marc Tatar

Summary: Mutations of the insulin-like receptor in Drosophila can extend lifespan through two modes of operation, one slowing reproduction and growth, and the other prolonging lifespan without impairing growth and reproduction. The structure of the insulin receptor can modulate aging by influencing the balance between reproduction and survival in fruit flies.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Cell Biology

The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells

Yu-Tzu Chan, Ruey-Jen Lin, Ya-Hui Wang, Tsai-Hsien Hung, Yenlin Huang, John Yu, Jyh-Cherng Yu, Alice L. Yu

Summary: This study reveals the crucial role of YAP in breast cancer stem cells. Knockdown of YAP reduces the viability and stemness of BCSCs in vitro and tumor formation in vivo. IGF-1R and IGF-1 regulate the expression and localization of YAP, and YAP overexpression increases the expression of IGF-1. Clinical analysis shows that high levels of YAP and IGF-1 are associated with shorter overall survival in basal-like breast cancer patients. In conclusion, the interplay between YAP and the IGF-1/IGF-1R pathway is clinically relevant for sustaining the properties of BCSCs.

CELL COMMUNICATION AND SIGNALING (2023)

Add to Collection

Article Biochemistry & Molecular Biology

AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R

Kang Li, Ke Song, Yuli Hou, Yuan Tian, Huijuan Wang, Libo Sun, Ang Li, Yonghong Zhang

Summary: The neuroblast differentiation-associated protein AHNAK plays an important role in hepatocellular carcinoma by interacting with insulin-like growth factor 1 receptor and promoting tumor growth.

MOLECULES (2022)

Add to Collection

Review Oncology

IGF-1R targeting in cancer - does sub-cellular localization matter?

Upendra K. Soni, Liam Jenny, Rashmi S. Hegde

Summary: The insulin-like growth factor receptor (IGF-1R) has been extensively studied as a potential target in oncology, but the initial promise has not been fulfilled due to resistance mechanisms and toxicities. Lack of patient stratification based on biomarkers in previous clinical trials has been recognized as a limitation. There is now growing interest in revisiting IGF-1R targeted therapeutics with predictive biomarker-driven patient stratification. The sub-cellular localization of IGF-1R has emerged as a potential biomarker.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Drugging IGF-1R in cancer: New insights and emerging opportunities

Panpan Wang, Victor C. Y. Mak, Lydia W. T. Cheung

Summary: The insulin-like growth factor (IGF) axis plays important roles in cancer development and metastasis. The type 1 IGF receptor (IGF-1R) is a key member in the IGF axis and has been recognized for its oncogenic role in multiple cancer lineages. This article reviews the occurrence of IGF-1R aberrations and activation mechanisms in cancers, and discusses the available therapeutic agents for IGF-1R inhibition, including antisense oligonucleotide, tyrosine kinase inhibitors, and monoclonal antibodies. Combination therapy targeting IGF-1R and other oncogenic vulnerabilities has shown promise, and new concepts such as blockage of nuclear translocation of IGF-1R are being explored to improve therapeutic efficacy.

GENES & DISEASES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Insulin-like growth factor signalling and its significance as a biomarker in fish and shellfish research

S. Chandhini, Bushra Trumboo, Seena Jose, Tincy Varghese, M. Rajesh, V. J. Rejish Kumar

Summary: The insulin-like growth factor signalling system plays a crucial role in the growth and development of fishes and shellfishes, serving as important biomarkers for assessing growth and nutritional status in aquaculture.

FISH PHYSIOLOGY AND BIOCHEMISTRY (2021)

Add to Collection

Article Cell Biology

Diversity of insulin and IGF signaling in breast cancer: Implications for therapy

Michael W. Lero, Leslie M. Shaw

Summary: This review underscores the significance of the IR/IGF-1R signaling pathway in cancer and its potential as a therapeutic target. Understanding the pathway's role in normal mammary gland function provides insight into its aberrations in breast cancer. However, efforts to target this pathway for cancer treatment are hindered by a lack of biomarkers and adverse effects on normal metabolism.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets

Yinqi Zhang, Chengqi Gao, Fei Cao, Ying Wu, Shuanggang Chen, Xue Han, Jingqin Mo, Zhiyu Qiu, Weijun Fan, Penghui Zhou, Lujun Shen

Summary: IGF-1 and IGF-1R show inconsistent gene expression levels in various cancer cell lines, with high expression typically detected in most malignant tumors. High expression of IGF-1 is closely associated with unfavorable overall survival in BLCA, CHOL, and LAML patients, while high expression of IGF-1R is closely linked to poor overall survival in BLCA, LIHC, and LUAD patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

Yongsheng Liu, Shengze Yu, Tianqi Xu, Vitalina Bodenko, Anna Orlova, Maryam Oroujeni, Sara S. Rinne, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjorn Graslund

Summary: This study evaluated the use of Ga-68 and In-111-labeled affibody construct NODAGA-(HE)(3)-Z(IGF-1R:4551) for the imaging of IGF-1R expression using PET and SPECT techniques. The results showed that these imaging probes could specifically bind to IGF-1R both in vitro and in vivo, demonstrating their potential for visualizing IGF-1R expression in malignant tumors.

PHARMACEUTICS (2022)

Add to Collection

Article Cell Biology

The basic route of nuclear-targeted transport of IGF-1/IGF-1R and potential biological functions in intestinal epithelial cells

Ming Xiu, Xia Huan, Yang Ou, Sha Ying, Jianmeng Wang

Summary: The study investigated the cellular behavior and characteristics of IGF-1/IGF-1R in intestinal cells, revealing that IGF-1 can internalize into the cytoplasm and transport into the cell nuclei. It was found that IGF-1R undergoes clathrin-mediated endocytosis and enters into Rab-5-positive endosomes before being transported to the cell nuclei along microtubules, promoting cell proliferation.

CELL PROLIFERATION (2021)

Add to Collection

Article Hematology

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia

Rudy Birsen, Clement Larrue, Justine Decroocq, Natacha Johnson, Nathan Guiraud, Mathilde Gotanegre, Lilia Cantero-Aguilar, Eric Grignano, Tony Huynh, Michaela Fontenay, Olivier Kosmider, Patrick Mayeux, Nicolas Chapuis, Jean Emmanuel Sarry, Jerome Tamburini, Didier Bouscary

Summary: APR 246 is a promising therapeutic agent for myelodysplastic syndromes and acute myeloid leukemia that targets p53 mutated proteins. It has been found to reactivate the transcriptional activity of p53 mutants and induce p53-independent cell death. The study also demonstrates the association between APR 246 and ferroptosis, a recently described cell death process. The detoxification capacity of AML cells to maintain glutathione biosynthesis may play a key role in determining sensitivity to APR 246.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

Shan Lin, Clement Larrue, Nastassja K. Scheidegger, Bo Kyung A. Seong, Neekesh Dharia, Miljan Kuljanin, Caroline S. Wechsler, Guillaume Kugener, Amanda L. Robichaud, Amy Saur Conway, Thelma Mashaka, Sarah Mouche, Biniam Adane, Jeremy A. Ryan, Joseph D. Mancias, Scott T. Younger, Federica Piccioni, Lynn H. Lee, Mark Wunderlich, Anthony Letai, Jerome Tamburini, Kimberly Stegmaier

Summary: This study utilized CRISPR screening to identify and validate AML-specific dependencies in vivo, including metabolic vulnerability and apoptosis regulator, providing an important strategy for discovering and prioritizing AML therapeutic targets.

CANCER DISCOVERY (2022)

Add to Collection

Article Hematology

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez, Jeremie Zerbit, Timothee Bruel, Amani Ouedrani, Delphine Planas, Paul Deschamps, Isabelle Staropoli, Jerome Hadjadj, Bruno Varet, Natalia Ermak, Didier Bouscary, Lise Willems, Guillemette Fouquet, Justine Decroocq, Patricia Franchi, Benedicte Deau-Fischer, Benjamin Terrier, Jerome Tamburini, Lucienne Chatenoud, Olivier Schwartz, Marguerite Vignon

BLOOD (2022)

Add to Collection

Article Medical Laboratory Technology

Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Bene, Peter Valent, Jeroen te Marvelde, Orianne Wagner-Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink-Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiss, Wolfgang Kern, Arjan van de Loosdrecht

Summary: This article reviews the progress of flow cytometry (FCM) in the diagnosis of myelodysplastic syndrome (MDS) in recent years, and provides optimal methods and recommendations for sample processing, antibody panels and fluorochromes, and current hardware technologies. These recommendations will facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients, but further standardization and harmonization are needed.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

Add to Collection

Article Medical Laboratory Technology

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A. Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. Marvelde, Sergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Marie C. Bene, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland

Summary: This article discusses the rationale for including flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group. The WHO 2016 classification acknowledges the contribution of FCM in the diagnosis of MDS and its potential usefulness in prognostication, prediction, therapy evaluation, and patient follow-up.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

Add to Collection

Letter Hematology

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

Amira Marouf, Anne Segolene Cottereau, Salim Kanoun, Paul Deschamps, Michel Meignan, Patricia Franchi, David Sibon, Clara Antoine, Thomas Gastinne, Cecile Borel, Mohammad Hammoud, Guillaume Sicard, Romane Gille, Doriane Cavalieri, Aspasia Stamatoullas, Lauriane Filliatre-Clement, Julien Lazarovici, Adrien Chauchet, Luc-Matthieu Fornecker, Sandy Amorin, Mathieu Rocquet, Nicole Raus, Barbara Burroni, Marie Therese Rubio, Didier Bouscary, Philippe Quittet, Rene Olivier Casasnovas, Pauline Brice, Herve Ghesquieres, Jerome Tamburini, Benedicte Deau

HAEMATOLOGICA (2022)

Add to Collection

Letter Oncology

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

Estelle Balducci, Sophie Kaltenbach, Patrick Villarese, Eugenie Duroyon, Loria Zalmai, Chloe Friedrich, Felipe Suarez, Ambroise Marcais, Didier Bouscary, Justine Decroocq, Rudy Birsen, Michaela Fontenay, Marie Temple, Chantal Brouzes, Aurore Touzart, Thomas Steimle, Agata Cieslak, Ludovic Lhermitte, Carole Almire, Nicolas Chapuis, Olivier Hermine, Vahid Asnafi, Olivier Kosmider, Lucile Couronne

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

Camille Chenevier-Gobeaux, Morgane Ducastel, Jean-Francois Meritet, Yassine Ballaa, Nicolas Chapuis, Frederic Pene, Nicolas Carlier, Nicolas Roche, Tali-Anne Szwebel, Benjamin Terrier, Didier Borderie

Summary: This study found that endocan is associated with thrombotic events in COVID-19 patients and may serve as a useful biomarker. Endocan concentrations increased with the severity of the disease, and patients experiencing thrombotic events had significantly higher levels of endocan. Combining endocan measurement with D-dimers improved the identification of thrombotic events. The combination of endocan and D-dimers better discriminated patients with thrombotic events. The combination of D-dimers and endocan was independently associated with thrombotic events.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Methaemoglobinaemia and haemolysis after rasburicase administration in a patient with G6PD deficiency

Ismael Boussaid, Johanna Mondesir, Nicolas Chapuis, Rudy Birsen

BMJ CASE REPORTS (2022)

Add to Collection

Review Medical Laboratory Technology

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Anna Porwit, Marie C. Bene, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner-Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink-Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson, Michael R. Loken, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Leonie Saft, Dolores Subira, Jeroen te Marvelde, Denise A. Wells, Vincent H. J. van der Velden, Wolfgang Kern, Arjan A. van de Loosdrecht

Summary: Multiparameter flow cytometry (MFC) is an essential method in bone marrow investigation for patients with cytopenia and suspected myelodysplastic syndrome (MDS), providing valuable information for diagnosis and treatment follow-up. This document summarizes recommendations from the ELN iMDS Flow on analytical issues in MFC, including the analysis of different cell subsets and the use of specific markers for MDS diagnosis. Machine-learning-based analytical tools and large uniform datasets are suggested for future research to improve integrated diagnostics and risk stratification in MDS.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

Add to Collection

Article Oncology

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia

Clement Larrue, Sarah Mouche, Shan Lin, Federico Simonetta, Nastassja K. Scheidegger, Laury Poulain, Rudy Birsen, Jean-Emmanuel Sarry, Kimberly Stegmaier, Jerome Tamburini

Summary: Mitochondrial fusion is a critical dependency in acute myeloid leukemia (AML). Inhibition of mitochondrial fusion through genetic depletion or pharmacological inhibition showed significant anti-leukemic activity in patient-derived xenograft (PDX) models, without impacting normal hematopoietic cells. Mechanistically, disruption of mitochondrial fusion led to cell cycle arrest and impaired mitochondrial respiration and reactive oxygen species production. These findings suggest that inhibition of mitochondrial fusion holds promise as a therapeutic approach for AML.

LEUKEMIA (2023)

Add to Collection

Article Hematology

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

J. Dufour, S. Choquet, K. Hoang-Xuan, A. Schmitt, G. Ahle, R. Houot, L. Taillandier, R. Gressin, O. Casasnovas, J. P. Marolleau, J. Tamburini, C. Serrier, E. Perez, J. Paillassa, E. Gyan, A. Chauchet, R. Ursu, A. Kas, C. Soussain, C. Houillier

Summary: This nationwide population-based study found rare extracerebral relapses of primary central nervous system lymphomas (PCNSL). The extracerebral relapses were mainly found in visceral organs (particularly testis and breast) and the peripheral nervous system. The prognosis was worse for mixed relapses. The study suggests the use of PET-CT in diagnosis and paired tumor analysis at diagnosis/relapse to better understand the underlying molecular mechanisms.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

A. Marouf, N. Molinari, D. Sibon, A. S. Cottereau, S. Kanoun, C. Antoine, P. E. Debureaux, D. Cavalieri, L. M. Fornecker, R. O. Casasnovas, C. Herbaux, S. Amorim, C. Rossi, D. Bouscary, P. Brice, H. Ghesquieres, J. Tamburini, B. Deau

Summary: Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for high-risk relapsed/refractory Hodgkin lymphoma (R/R HL) patients. Maintenance therapy with Brentuximab Vedotin (BV) after ASCT has been shown to improve survival in BV-naive patients. In this study, BV maintenance was compared to tandem transplant strategies and was found to be associated with better survival outcomes in patients with high-risk R/R HL.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

C/EBP & alpha; Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia

Marie Sabatier, Rudy Birsen, Laura Lauture, Sarah Mouche, Paolo Angelino, Jonas Dehairs, Ismael Boussaid, Mael Heiblig, Emeline Boet, Ambrine Sahal, Estelle Saland, Juliana C. Santos, Marc Armengol, Miranda Fernandez-Serrano, Thomas Farge, Guillaume Cognet, Federico Simonetta, Corentin Pignon, Antoine Graffeuil, Celine Mazzotti, Herve Avet-Loiseau, Oceane Delos, Justine Bertrand-Michel, Amelie Chedru, Vilma Dembitz, Paolo Gallipoli, Natasha S. Anstee, Sun Loo, Andrew H. Wei, Martin Carroll, Armelle Goubard, Remy Castellano, Yves Collette, Francois Vergez, Veronique Mansat-De Mas, Sarah Bertoli, Suzanne Tavitian, Muriel Picard, Christian Recher, Nathalie Bourges-Abella, Fanny Granat, Olivier Kosmider, Pierre Sujobert, Benoit Colsch, Carine Joffre, Lucille Stuani, Johannes V. Swinnen, Herve Guillou, Gael Roue, Nawad Hakim, Anne S. Dejean, Petros Tsantoulis, Clement Larrue, Didier Bouscary, Jerome Tamburini, Jean-Emmanuel Sarry

Summary: Although the role of CCAAT-enhancer binding protein α (C/EBPα) in cancer cell and metabolic homeostasis is largely unknown, this study reveals its coordination with FLT3 in lipid anabolism and its regulation of fatty acid biosynthesis and desaturation. Furthermore, FLT3 or C/EBPα inactivation decreases monounsaturated fatty acid incorporation and renders FLT3-mutant AML cells vulnerable to ferroptosis. This finding suggests a promising therapeutic potential for targeting FLT3-mutant AML cells.

CANCER DISCOVERY (2023)

Add to Collection

Letter Hematology

Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study

Maya Belhadj, Barbara Burroni, Olivier Kosmider, Lise Willems, Marie Temple, Sarah Bertoli, Corentin Orvain, Pierre-Yves Dumas, Celine Berthon, Ludovic Gabellier, Ambroise Marcais, Emmanuel Raffoux, Cecile Pautas, Alexis Genthon, Justine Decroocq, Rudy Birsen, Jerome Tamburini, Didier Bouscary, Adrien Contejean

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.